This biotech stock just surged 234% to $45.63 - here's what investors need to know
Key Points
- UniQure's stock soared 234% after their gene therapy treatme...
UniQure just pulled off what might be the biotech equivalent of hitting the lottery - except this time, it wasn't pure luck. The company's stock launched into orbit with a jaw-dropping 234% surge to $45.63, and for once, there's actually solid science behind the celebration.
When Gene Therapy Actually Works
The catalyst? Their AMT-130 treatment for Huntington's Disease just delivered results that would make any pharmaceutical executive weep tears of joy. The Phase I/II trial showed a 75% reduction in disease progression over 36 months, along with meaningful improvements in motor and cogn...
While we have taken every measure to build an AI pipeline that generates credible and accuracte news, we still encourage you to conduct your own research before making investment decisions. InsAIght's content should not be considered professional financial or trading advice.